Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen for Social Withdrawal in ASD
NCT01288716Phase 2Completed
- Sponsor
- Seaside Therapeutics
- Start
- May 2011
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Arbaclofen with Placebo (2 arms). Primary endpoint: Aberrant Behavior Checklist-Social Withdrawal Subscale at 8 weeks. Started May 2011; status: completed.
02
Drugs
arbaclofen
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01288716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01288716.